BUSINESS

• Dupixent 200 mg Syringe Now Available in Japan: Sanofi
  December 19, 2023

• Shionogi, Sobi Ink Fetcroja Distribution Pact for 13 European Countries
  December 19, 2023

• Shionogi Kicks Off PIII Booster Trial for XBB1.5 COVID Vaccine in Japan
  December 19, 2023

• Takeda’s Hyqvia Gets EU Panel Backing for CIDP Maintenance Therapy
  December 19, 2023

• Padcev/Keytruda Combo Nabs FDA Nod for 1st Line Bladder Cancer
  December 19, 2023

• Eisai Files Tasurgratinib for Biliary Tract Cancer in Japan
  December 19, 2023

• Terumo’s Next CEO Resolved to Drive Biologics Forward, Fulfill Diverse Demands
  December 18, 2023

• Eisai CEO Anticipates Leqembi Approval in Europe and China by March
  December 18, 2023

• Alecensa Filed for Adjuvant Therapy for ALK-Positive NSCLC: Chugai
  December 18, 2023

• Cheplapharm Initiates LLP Acquisitions in Japan, Eyes 10 Asset Takeovers in 2024: Local Head
  December 15, 2023

• Taisho Aims to Make “Alli” 5th Leg of Its Consumer Healthcare Biz, Eyes Annual Sales of 2-3 Billion Yen
  December 15, 2023

• JCR Bags FDA’s Orphan Tag for MPS IIIA Drug in US
  December 15, 2023

• Shionogi Ships 1st Batch of Cough Drug Medicon after Ramp-Up
  December 15, 2023

• Leqembi to Debut on Dec. 20; Eisai Sees SC Version and Blood Biomarker as Drivers for Wider Use
  December 14, 2023

• Novo Nordisk Expects to Lift Restrictions on Ozempic Shipments in Early January
  December 14, 2023

• Torii Scoops Up Japan Rights for Grass Pollinosis Med
  December 14, 2023

• Avastin Biosimilars Add Malignant Glioma Indication in Japan
  December 14, 2023

• Prograf Generics Now on Equal Footing with Original Product
  December 14, 2023

• Mochida Intends to Carve Out Market Share with 1st G-Lasta Biosimilar
  December 13, 2023

• GSK Seeks Label Expansion of Arexvy for High-Risk Adults Aged 50-59
  December 13, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 110
• 111
• 112
• 113
• 114
• 115
• 116
• 117
• 118
• …
• Next ›
• 最終 »